Obesity medicine is an ever-changing speciality which is exciting but also requires frequent updates. 2023 was a year of new medications, treatments, and guidelines. All updates discussed below have been incorporated into the 2024 edition.
These are updates to the 2023 edition of the blue book since publication. A short description is provided in the left hand column, whereas the right hand column refers to the question numbers affected.
In the question stem, the patient's arm circumference should be 36 cm.
The Aspire Assist® Device was electively discontinued in 2022 due to financial constraints, not safety or efficacy. This device may show up on test day (contraindications, complications, etc.) given that patients may have had this procedure done, but would not be the preferred weight-loss treatment option anymore given its lack of availability.
The 2023 updated AAP guidelines have now replaced the staged approach to pediatric obesity. This is a big change to the long-tested and utilized prior recommendations. Check back here for updated replacement questions or subscribe to the blog to be notified when these questions become available. Review new guidelines here.
Answer choice B is also a surgical candidate. Answer D is likely still the best option given a number of comorbidities, but both are current surgical candidates.
Semaglutide (Wegovy ® ) is now approved for chronic weight-management in those 12 years and older.
ReShape™ (dual-balloon system) has been bought out by Orbera™ (single-balloon system), who has since discontinued ReShape™ production. Also, Spatz 3™ has been approved (first adjustable balloon that can stay in place 8 months instead of 6), as well as Obalon™ (first swallowable balloon, with up to 3 balloons being deployed at 2 week intervals) is now approved in those > 22 years old.
This question states in the explanation that cellulose and citric acid hydrogel decreases satiety. It should read as: Cellulose and citric acid hydrogel (brand name Plenity®) is a volume-occupying treatment for those with a BMI of 25-40kg/m2. It is taken before meals to increase satiety.
These are updates to the 2023 edition of the red book since publication. The right hand column refers to the question numbers affected.
See comments above.
See comments above.
Answer D should be androgenic alopecia (not adrenergic)
See comments above.
See comments above.
Please note, that given the recency of these updates, they may not affect the upcoming testing window.
Obesity Medicine Board Review Questions
Copyright © 2024 Obesity Medicine Board Review Questions - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.